Apollo Health provides the first real hope for Alzheimer’s. We are a medical information company that uses high-tech software to provide solutions for one of the leading causes of death worldwide.

Thirty-plus years of medical research has put Dr. Dale Bredesen, the Chief Science Officer of Apollo Health, at the forefront of research into Alzheimer’s disease prevention and memory-loss reversal. His research teams have made discoveries that changed our understanding of Alzheimer’s disease’s fundamental nature leading to revolutionary treatments.

Dr. Bredesen’s research has found that Alzheimer’s results from an imbalance in the brain’s neuroplasticity signaling, the ability of neural networks in the brain to change through growth and reorganization. As we age and are exposed to multiple toxic assaults over time, the damaging forces overtake repair forces, resulting in the downsizing of the brain’s ability and subsequent cognitive decline. The goal is to change your biochemistry to provide optimal conditions for your brain to thrive. This is accomplished by identifying and addressing all the contributors (or potential contributors) to cognitive decline while at the same time optimizing your overall health to keep your brain healthy.


This approach is known as the Bredesen Protocol®. The protocol is designed to reverse the effects of subjective cognitive impairment (SCI), mild cognitive impairment (MCI) and early Alzheimer’s disease. We offer the Bredesen Protocol through two subscription programs, the PreCODE Program (for prevention) and ReCODE Program™ (for reversal.)

To learn which program is right for you, take our free cognitive assessment. Knowledge is power. Learn where you stand today and take control of your cognitive health for decades to come. 

Alzheimer’s is a disease for which there is no cure. Dr. Bredesen’s experimental program gives me hope that there are actions we can all take to care for our brains and keep Alzheimer’s at bay.

Maria Shriver

Today Show

75 Million

There are 75 million Americans with ApoE4, the most important genetic risk factor for Alzheimer’s disease.


It is expected that by 2050, there will be over 160,000,000 patients with Alzheimer’s disease globally.

$200 billion

In the United States alone, over five million people suffer from Alzheimer’s disease, at an estimated annual cost of $200 billion, and a projection for 13 million patients by 2050.


Apollo Health brings together some of the world’s top experts to help you and your family live better, more healthy lives. Learn about this dedicated team on our leadership page.

Learn More

In the Media

We’re on the cutting edge of innovation in the field of Alzheimer’s research, prevention, and treatment. Learn more news about our company and our mission on our media page.

Learn More


We would love to hear from you. If you have any questions or comments about Apollo Health, PreCODE, ReCODE, or other inquiries, please reach out on our contact page.

Learn More